Leerink Partners Issues Pessimistic Forecast for Kardigan (NASDAQ:KARD) Stock Price

Kardigan (NASDAQ:KARD) had its price target decreased by equities research analysts at Leerink Partners from $37.00 to $36.00 in a report released on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners‘s target price indicates a potential upside of 160.49% from the company’s previous close.

Several other research analysts have also recently commented on the stock. Robert W. Baird initiated coverage on shares of Kardigan in a report on Wednesday, October 21st. They issued an “outperform” rating and a $43.00 target price for the company. HC Wainwright initiated coverage on shares of Kardigan in a research report on Wednesday, November 4th. They issued a “buy” rating and a $42.00 target price on the stock. JPMorgan Chase & Co. cut their price target on shares of Kardigan from $51.00 to $46.00 and set an “overweight” rating on the stock in a report on Tuesday, August 25th. Cantor Fitzgerald started coverage on shares of Kardigan in a report on Thursday, October 29th. They set an “overweight” rating and a $50.00 price target on the stock. Finally, UBS Group started coverage on shares of Kardigan in a research report on Monday, October 12th. They issued a “buy” rating and a $25.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Kardigan Trading Down 2.1%

KARD traded down $0.30 during trading on Friday, reaching $13.82. The company had a trading volume of 410,885 shares, compared to its average volume of 511,833. The company has a 50-day moving average of $15.14. The firm has a market capitalization of $1.29 billion and a P/E ratio of -4.80. Kardigan has a 12-month low of $12.23 and a 12-month high of $27.00.

Kardigan (NASDAQ:KARD) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.16. Analysts anticipate that Kardigan will post -3.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kardigan

Several large investors have recently made changes to their positions in KARD. Jupiter Topco LLC acquired a new position in Kardigan in the second quarter worth approximately $17,715,000. State Street Corp acquired a new stake in Kardigan in the third quarter valued at approximately $6,721,000. Montanova Capital LLC acquired a new stake in Kardigan in the second quarter valued at approximately $9,540,000. Bank of New York Mellon Corp acquired a new stake in Kardigan in the second quarter valued at approximately $9,010,000. Finally, Braidwell LP bought a new stake in Kardigan in the second quarter worth approximately $7,155,000.

Trending Headlines about Kardigan

Here are a few of the latest headlines about KARD:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $42 price target. It also raised its FY2026 estimate to a loss of $3.70 per share from $4.01, and improved estimates for FY2028, FY2029 and FY2030. Kardigan analyst estimates
• Negative Sentiment: The firm cut estimates for multiple 2027 quarters and lowered its FY2027 forecast to a loss of $3.47 per share from $3.29, signaling expectations for higher losses over that period. A separate Leerink Partners update trimmed its price target to $36 from $37, though it retained an Outperform rating.

Kardigan Company Profile

Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company’s activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.